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se conardiac arrest due to torsade de pointes (TdP) in
the acquired form of drug-induced long-QT syn-
drome (LQTS) is a rare but potentially cata-
trophic event in hospital settings. Administration of a
T-prolonging drug to a hospitalized population may be
ore likely to cause TdP than administration of the same
rug to an outpatient population, because hospitalized
atients often have other risk factors for a proarrhythmic
esponse. For example, hospitalized patients are often
lderly people with underlying heart disease who may also
ave renal or hepatic dysfunction, electrolyte abnormali-
ies, or bradycardia and to whom drugs may be adminis-
ered rapidly via the intravenous route.
In hospital units where patients’ electrocardiograms
ECGs) are monitored continuously, the possibility of TdP
ay be anticipated by the detection of an increasing QT
nterval and other premonitory ECG signs of impending
rrhythmia. If these ECG harbingers of TdP are recognized, it
hen becomes possible to discontinue the culprit drug and
anage concomitant provocative conditions (e.g., hypokale-
ia, bradyarrhythmias) to reduce the occurrence of cardiac
rrest.
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ospital settings, and immediate management of marked QT
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haracteristic Pattern of TdP
he term torsade de pointes was coined by Dessertenne in
966 as a polymorphic ventricular tachycardia characterized
y a pattern of twisting points (1). Several ECG features are
haracteristic of TdP and are illustrated in Figure 1. First, a
hange in the amplitude and morphology (twisting) of the
RS complexes around the isoelectric line is a typical feature
f the arrhythmia; however, this characteristic twisting mor-
hology may not be evident in all ECG leads. Second,
pisodes of drug-induced TdP usually start with a short-long-
undation make every effort to avoid any actual or potential conflicts of
ional, or business interest of a member of the writing panel. Specifically,
re Questionnaire showing all such relationships that might be perceived
dvisory and Coordinating Committee on October 30, 2009, and by the
, 2009.
nt be cited as follows: Drew BJ, Ackerman MJ, Funk M, Gibler WB,
erican Heart Association Acute Cardiac Care Committee of the Council
an College of Cardiology Foundation. Prevention of torsade de pointes
nd the American College of Cardiology Foundation. J Am Coll Cardiol
.
can Heart Association (my.americanheart.org) and the American College
tact Elsevier Inc. Reprint Department, fax 212-633-3820, e-maildistribution of this document are not permitted without the express
Elsevier’s permission department at healthpermissions@elsevier.com.
sh
pr
sa
th
un
th
ve
fo
sh
in
di
ph
di
m
pe
Fo
te
sp
th
in
po
ar
th
Q
ap
P
L
w
in
in
m
th
ha
pa
pr
co
as
ca
T

ri
du
in
(1
th
pr
ob
ha
th
m
T
be
pr
(t
of
T
fu
th
de
T
be
fr
be
ef
tr
an
tr
on
bu
ar
to
E
(1
po
m
av
di
of
C
Pr
m
fu
Fi
ch
th
di
to
ph mplexe
935JACC Vol. 55, No. 9, 2010 Drew et al.
March 2, 2010:934–47 Prevention of Torsade de Pointes in Hospital Settingsort pattern of R-R cycles consisting of a short-coupled
emature ventricular complex (PVC) followed by a compen-
tory pause and then another PVC that typically falls close to
e peak of the T wave (2). However, because of the
derlying long-QT interval, this R-on-T PVC does not have
e short coupling interval that is characteristic of idiopathic
ntricular fibrillation. On the basis of experiments per-
rmed in isolated canine ventricular wedge preparations, this
ort-long-short sequence is thought to promote TdP by
creasing heterogeneity of repolarization across the myocar-
al wall. Third, TdP episodes usually show a warm-up
enomenon, with the first few beats of ventricular tachycar-
a exhibiting longer cycle lengths than subsequent arrhyth-
ia complexes. The rate of TdP ranges from 160 to 240 beats
r minute, which is slower than ventricular fibrillation.
urth, in contrast to ventricular fibrillation that does not
rminate without defibrillation, TdP frequently terminates
ontaneously, with the last 2 to 3 beats showing slowing of
e arrhythmia. However, in some cases, TdP degenerates
to ventricular fibrillation and causes sudden cardiac death.
The term torsade de pointes has also been used to describe
lymorphic ventricular arrhythmias in which QT intervals
e not prolonged. However, the term is better confined to
ose polymorphic tachycardias with marked (500 ms)
T-interval prolongation and QT-U deformity, because they
pear to be a distinct mechanistic and therapeutic entity.
remonitory ECG Signs of TdP
essons learned from research in large cohorts of individuals
ith congenital LQTS indicate that there is a gradual increase
risk for TdP as the heart rate–corrected QT interval (QTc)
creases. Each 10-ms increase in QTc contributes approxi-
ately a 5% to 7% exponential increase in risk for TdP in
ese patients (3,4). Therefore, a patient with a QTc of 540 ms
s a 63% to 97% higher risk of developing TdP than a
tient with a QTc of 440 ms. There is no threshold of QTc
olongation at which TdP is certain to occur. Data from
ngenital LQTS studies (5,6) indicate that a QTc500 ms is
sociated with a 2- to 3-fold higher risk for TdP. Likewise,
se reports and small series of patients with drug-induced
dP show similar increased risk when the threshold of QTc
500 ms is exceeded (7–9).
Although research in congenital LQTS indicates that the
gure 1. Onset of TdP during the recording of a standard 12-lead
ronic methadone therapy who presented to a hospital emergenc
e-counter drugs from his parent’s drug cabinet. Classic ECG fea
storted T-U complex, initiation of the arrhythmia after a short-lon
rted T-U complex, “warm-up” phenomenon with initial R-R cycle
ology from predominately positive to predominately negative cosk for syncope and sudden death varies directly with the inration of the QT interval (5), monitoring the QT/QTc
tervals alone may be inadequate to accurately predict TdP
0). One reason QT monitoring alone may be inadequate is
at it is difficult to measure this interval accurately in clinical
actice and in clinical trials. Automated systems and human
servers are reasonably adept at measuring QT intervals that
ve normal duration and morphology; however, establishing
e end of the QT interval that is morphologically distorted is
uch more challenging and prone to interrater differences.
he typical short-long-short sequence of R-R intervals seen
fore the initiation of TdP is associated with marked QT
olongation and T-U–wave distortion in the last sinus beat
erminating the long pause) before the episode. Distortion
ten involves changes in T-wave morphology such as
-wave flattening, bifid T waves, prominent U waves that are
sed with T waves, and an extended and gradual sloping of
e descending limb of the T wave, which makes it difficult to
termine the end of the T wave. Some reports indicate that
dP is especially likely when the QT interval is prolonged
cause of an increase in the terminal portion of the T wave,
om the peak of the T wave to its end (Tpeak-Tend) (11,12).
In a patient with drug-induced LQTS, the QT interval may
prolonged during normal sinus rhythm without adverse
fect, but after a pause (e.g., after an ectopic beat or during
ansient atrioventricular block), QT-interval prolongation
d T-U deformity become markedly exaggerated, and TdP is
iggered. This beat-to-beat instability of the QT interval not
ly appears likely to influence the accuracy of measurement,
t it may also be related to the underlying mechanism of the
rhythmia (13). In addition to an ever-increasing and dis-
rted QT interval, another rare but ominous premonitory
CG sign of impending TdP is macroscopic T-wave alternans
4), as illustrated in Figure 2. In the future, it may be
ssible to assess risk by use of sophisticated T-U–wave
orphology analysis; however, until such analysis becomes
ailable, exaggerated QT-interval prolongation with T-U
stortion after a pause should be considered a strong marker
risk for TdP.
ellular Mechanisms of Acquired LQTS
olongation of the QT interval, changes in T-U wave
orphology, and subsequent TdP are results of abnormal
nction (and structure) of ion channels and related proteins
in a young male with a history of drug addiction treated with
rtment after ingesting an overdose of prescription and over-
vident in this rhythm strip include a prolonged QT interval with
t cycle sequence by a PVC that falls near the peak of the dis-
r than subsequent cycles, and abrupt switching of QRS mor-
s (asterisk).ECG
y depa
tures e
g-shor
s longevolved in the repolarization process in ventricular myo-
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Prevention of Torsade de Pointes in Hospital Settings March 2, 2010:934–47tes. These abnormalities can be caused by mutations of
nes that encode ion channels or associated proteins in
ngenital forms of LQTS; however, they can also be caused
the action of drugs in acquired LQTS. Drugs with the
tential to cause TdP most frequently inhibit the rapid
mponent of the delayed rectifier potassium current (IKr),
hich causes a reduction in the net repolarizing current and
sults in prolongation of the ventricular action potential
ration and a prolonged QT interval on the ECG (15).
Experiments in canine ventricular wedge preparations have
own that in normal circumstances, there are differences in
polarization in the various layers of the myocardium, with
e subepicardium having the shortest action potential dura-
n, the subendocardium having an intermediate duration,
d the mid myocardium (M cells) having the longest action
tential duration (16,17). However, because the myocardial
yers are tightly coupled in the intact human heart, such
fferences are small. Many reports indicate that the QT
terval on the ECG represents the longest repolarization in
e M-cell region. This physiological transmural dispersion of
polarization usually does not lead to TdP; however, proar-
ythmic states may arise as a result of specific gene
utations or actions of medications that cause selective
tion potential prolongation in certain layers of the myocar-
um (usually the M-cell region) that lead to increased
ansmural repolarization gradients (17). This increased trans-
ural gradient is thought to create the conditions for reentry
d subsequent TdP.
The trigger for TdP is thought to be a PVC that results from
early afterdepolarization generated during the abnormally
olonged repolarization phase of the affected myocardium
8). A long preceding pause increases the amplitude of early
terdepolarizations, which makes them more likely to reach
gure 2. Top rhythm strip, TdP degenerating into ventricular fibril
r pneumonia. She was started on intravenous erythromycin seve
use provided the short-long-short cycle sequence that triggered
ows extreme prolongation of the QT interval (QTc in cycles with
opic T-wave alternans (vertical arrows). If these signs of impend
ministration of magnesium most likely would have prevented thee threshold necessary to produce a PVC or ventricular pruplet. Because of the marked delay of repolarization in
rtain areas of the myocardium, conduction of the PVC is
ocked initially in some directions but not in others, which
ts up reentry that perpetuates TdP.
Not all QT-prolonging drugs are associated with risk for
dP. Therefore, it appears that QT prolongation alone is
sufficient and that heterogeneity of repolarization may also
necessary to produce an arrhythmogenic response. How-
er, the mechanisms whereby not all QT prolongation
nfers the same degree of risk are not well established.
Experts in electrocardiography, including members of this
riting group, have been curious about the peculiar pattern of
ne-wave QRS changes with TdP. El-Sherif et al. (19)
ovided an electrophysiological mechanism for the charac-
ristic periodic transition of the QRS axis during TdP. In an
perimental setting, they demonstrated that the initial beat of
dP arose as a subendocardial focal activity, whereas subse-
ent beats were due to reentrant excitation in the form of
tating scrolls. The arrhythmia ended when reentrant exci-
tion was terminated. The transition in the QRS axis coin-
ded with a transient bifurcation of the predominantly single
tating scroll into 2 simultaneous scrolls that involved both
e right ventricle and left ventricle separately. The common
echanism for the initiation or termination of this bifurcation
as the development of functional conduction block between
e anterior or posterior right ventricular free wall and the
ntricular septum.
enetic Susceptibility to Drug-Induced TdP
is becoming increasingly evident that genetic susceptibility,
hether due to the presence of rare LQTS-causing mutations
the presence of functional common polymorphisms, must
considered in the patient who manifests drug-induced QT
n an 83-year-old female hospitalized in the intensive care unit
rs before cardiac arrest. A ventricular couplet followed by a
ottom rhythm strip, ECG 1 hour before the onset of TdP
T waves730 ms), a ventricular couplet (asterisk), and macro-
had been recognized, discontinuation of the culprit drug and
quent cardiac arrest.lation i
ral hou
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March 2, 2010:934–47 Prevention of Torsade de Pointes in Hospital Settingsnital LQTS as a channelopathy with mutations identified in
nes encoding voltage-gated potassium and sodium chan-
ls in 1995 (20,21), nearly 1000 individually rare LQTS-
using mutations have now been detected in 12 distinct
QTS-susceptibility genes. Three of the 12 LQTS-
sceptibility genes (KCNQ1-encoded IKs -subunit [LQT1],
CNH2-encoded IKr -subunit [LQT2], and SCN5A-
coded Nav1.5 -subunit [LQT3]) are the major LQTS-
sceptibility genes, accounting for nearly 75% of all con-
nital LQTS cases (22).
Approximately two thirds of LQTS stems from loss-of-
nction mutations in either KCNQ1 or KCNH2 whereby
ere is a perturbation in phase 3 repolarization that results in
prolongation in the action potential duration and hence
T-interval prolongation. These defects provide the patho-
nic substrate on which an ill-timed PVC and its cellular
rly afterdepolarization can precipitate TdP. Besides the
edominant mechanism of potassium channel loss of func-
n, approximately 5% to 10% of LQTS stems from gain-
-function mutations in the sodium channel whereby the
utations (mostly missense, i.e., single amino acid substitu-
ns) produce a sodium channel with a marked accentuation
late sodium current. Rather than shutting down within the
st 5 ms of a cardiac action potential, this persistent but
latively small influx of inward sodium current disrupts
ase 2 of the fine-tuned balance of the action potential,
hich prolongs the cellular action potential duration and
nfers the substrate for TdP. In addition to these 3 major
QTS-susceptibility genes that account for 75% of congenital
QTS, 9 minor LQTS-susceptibility genes account for an
ditional 5%. The remaining 20% of congenital LQTS cases
main genotype negative.
From 1995 to 2004, research-based LQTS genetic testing
vealed a plethora of genotype-phenotype relationships,
cluding genotype-suggestive ECG patterns, arrhythmogenic
iggers, and genetically determined responses to pharmaco-
erapy. In 2004, LQTS genetic testing matured into a
inically available test because of its established diagnostic,
ognostic, and therapeutic implications. Just as a period of
e (e.g., during swimming or during the postpartum period)
n suggest the presence of congenital LQTS, drug-induced
ng QT and TdP may also signal the presence of an LQTS
netic defect. In fact, the yield from LQTS genetic testing
ith respect to the 3 major LQTS-susceptibility genes is
proximately 10% to 15% in individuals with isolated
ug-induced acquired LQTS (23–25).
In addition to these individually rare mutations that confer
sceptibility for the primary channelopathy known as con-
nital LQTS, which affects approximately 1 in 2500 persons,
merous common polymorphisms in these same cardiac
annel genes have been identified, and some are now known
contribute to a reduced repolarization reserve and confer a
odifier effect (26). For example, SCN5A-S1103Y is one of
e most common polymorphisms in black Africans, 10% to
% of whom may be heterozygous for this common,
nsynonymous single-nucleotide polymorphism. SCN5A-
103Y is now known to produce or acquire a cellular
enotype of accentuated late sodium current (LQT3-like)hen exposed to cellular acidosis and confer clinical suscep- prility to proarrhythmia and premature sudden death as early
infancy in African Americans (27–30). In addition,
CNE2-Q9E was published originally as a rare, LQT6-
using missense mutation after its identification in a 76-
ar-old African American female with profound QT prolon-
tion and TdP who required defibrillation after 7 doses of
travenous erythromycin and 2 doses of oral clarithromycin,
th of which are known IKr blockers (31). Functional studies
monstrated that an IKr complex containing Q9E in the
CNE2-encoded -subunit resulted in a potassium channel
ith a marked increase in sensitivity to hERG (human
her-a-go-go) block by clarithromycin. However, in contrast
its initial impression of rarity (absence in more than 2000
ntrol alleles of unspecified ethnicity), KCNE2-Q9E is a
latively black-specific common polymorphism present in
proximately 3% to 5% of African Americans (32).
Case series of drug-induced TdP (usually involving anti-
rhythmic agents) identify subclinical congenital LQTS in
to 20% of cases (23–25). However, the extent to which
e congenital LQTS confers risk during administration of
ugs is not well understood. To illustrate the lack of clarity
out genetic susceptibility and drug risk, moxifloxacin is a
ug that very rarely causes TdP; however, the risk does not
pear to increase even in the presence of congenital LQTS
r the following reason. The incidence of TdP with moxi-
xacin is very low, 1:100 000 to 1:1 000 000 exposures.
oxifloxacin is pharmacokinetically well behaved, with no
own drug interactions or organ dysfunction that severely
ters plasma concentrations. Given the fact that the muta-
ns associated with congenital LQTS occur in 1 in 2500
dividuals in the population (33), it appears irrefutable that
any patients with congenital LQTS have been exposed to
e drug without adverse effects.
This kind of logic points to a likely distinction between
gh- and low-risk drugs. For example, the high-risk drugs,
ch as antiarrhythmic agents, methadone, and haloperidol,
ay increase risk for TdP in individuals with genetic muta-
ns, whereas the low-risk drugs, such as moxifloxacin, may
quire other risk factors such as electrolyte disorders.
rugs That Cause TdP:
cidence and Other Features
hen sudden death occurs without autopsy evidence for an
plainable cause of death, an arrhythmic death is assumed.
owever, the proportion of sudden arrhythmic deaths that are
e to TdP is unclear, because few individuals are being
onitored at the time of death. When TdP occurs in outpa-
nt settings, the first responders who arrive on the scene
ith portable monitor-defibrillators are likely to observe
ntricular fibrillation. In this situation, it is impossible to
termine whether ventricular fibrillation was preceded by
T prolongation and TdP. In hospital settings, the same lack
clarity about the arrhythmia mechanism that caused the
rdiac arrest may occur if a patient is not undergoing
ntinuous ECG monitoring at the time of arrest. Postarrest
CG changes are not uncommon, and a link to LQTS may not
made. For example, the postarrest QT interval may beolonged because of the hypoxic/anoxic insult, or it may be
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Prevention of Torsade de Pointes in Hospital Settings March 2, 2010:934–47ite short, presumably due to elevated potassium in this
tting.
Preclinical and early-phase clinical testing of new drugs
ay reveal a QT-prolongation signal that may be identified
consulting the drug label. Use of a QT-prolonging drug
ust be based on risk-benefit analysis in individual patients,
d where efficacy of alternatives is equivalent, the non–QT-
olonging agent should be preferred. Where benefit clearly
tweighs risk, QT prolongation should not limit necessary
erapy. QT prolongation is not necessarily equivalent to
rhythmogenicity. The only class of drugs for which reason-
le TdP incidence data are available is the antiarrhythmic
ents. Those known to prolong the QT interval and block
dium and potassium channels (older drugs such as quini-
ne, disopyramide, and procainamide), as well as those that
ock potassium channels (sotalol, dofetilide, ibutilide), ap-
ar to have a TdP incidence of 1% to 10% (34). For the older
ugs, the numbers are derived from uncontrolled case series,
hereas for the newer agents, summary data from clinical
ials and new drug applications are available (35–40).
Many non-antiarrhythmic drugs have also been associated
ith TdP. For some drugs, multiple case reports and small
se series confirm that the drug causes the arrhythmia.
igh-profile examples include methadone (41), thioridazine
2), and haloperidol (43). Although the absolute TdP inci-
nce is difficult to establish from these reports of non-
tiarrhythmic agents, it is generally believed to be less than
at reported for antiarrhythmic agents.
IKr inhibition is a very common effect of many drugs, and
se reports and small series implicate the involvement of
any such drugs with TdP. Some of these are widely and
mmonly used, such as erythromycin and droperidol. In
dition, a number of drugs have been withdrawn from the
arket or relabeled because of the risk for TdP (26). The
solute incidence figures are difficult to establish but appear
be very small, even in these cases of banned drugs. Thus,
r example, nearly one hundred million prescriptions for the
tihistamine terfenadine had been written before a very
all risk for TdP was recognized. The overall incidence of
dP with terfenadine is exceedingly small and appears to be
nfined largely to patients with specific risk factors related
metabolism of the drug (44).
For virtually all QT-prolonging drugs, risk increases as a
nction of dose and, more specifically, plasma drug concen-
ation, with the exception of quinidine. Quinidine is a potent
r blocker (45), so at low concentrations it may prolong
tion potentials, whereas this effect may be blunted (by the
ug’s sodium channel–blocking properties) at higher con-
ntrations, which explains the clinical observation that
inidine-induced TdP often occurs at low concentrations.
The high-potency IKr blocker terfenadine undergoes near-
mplete presystemic metabolism, mediated largely by a
ecific hepatic cytochrome P450 (CYP3A4). Both terfena-
ne and its metabolite fexofenadine are potent antihista-
ines, but fexofenadine does not block IKr (8); nevertheless,
ere is 1 case report of fexofenadine-related TdP (46). The
st majority of cases of terfenadine-associated TdP were
sociated with inhibition of CYP3A4 due to advanced liver
sease, overdose, or ingestion of specific inhibitor drugs, hitably erythromycin and ketoconazole. Erythromycin itself
n also cause TdP, almost always with high doses or with
e of the intravenous route and often in patients with other
sk factors (47).
The problem of dramatic drug accumulation due to use of
gh doses, dysfunction of organs of elimination, or interact-
g drugs applies to other situations. Dofetilide and sotalol are
eared by the kidneys, and the use of ordinary doses in
tients with renal failure increases TdP risk with these drugs.
ocainamide undergoes hepatic clearance to an active me-
bolite, N-acetylprocainamide (NAPA), which has IKr-
ocking properties. NAPA itself is eliminated by the kid-
ys, so patients with renal dysfunction may develop NAPA-
lated TdP during procainamide therapy (37). Thioridazine
bioinactivated by CYP2D6, and subjects with deficient
tivity of this enzyme due to genetic factors (5% to 10% of
hite and black populations) or the use of CYP2D6-
hibiting drugs such as quinidine, fluoxetine, or paroxetine
ve higher plasma drug concentrations (48).
Case series of methadone-related TdP indicate that the use
high doses and/or recent dose increases are common
inical features of affected patients (41). Methadone is
eared by multiple pathways; although inhibiting drugs have
en implicated, their precise role is unclear at this time.
early 1 million Americans use methadone for narcotic
pendence or for chronic pain therapy (49). Recently pub-
hed methadone clinical guidelines recommend a pretreat-
ent ECG for QTc interval screening and a follow-up ECG
ithin 30 days and then annually (49).
The risk for TdP should be evaluated in any patient who
esents to the emergency department with an overdose of a
T-prolonging drug. However, because it is often unclear
hat drug or combination of drugs the patient may have
ken, the ECG of all drug overdose victims should be
sessed for signs of prolonged QT, QT-U distortion, and
her signs of impending TdP (Figure 2). The tricyclic
tidepressants such as amitriptyline can cause TdP, although
e incidence is not well established and other arrhythmias
e to sodium channel blocker toxicity (e.g., wide QRS and
nusoidal ventricular tachycardia) may also be present. Less
equent use of these antidepressants for outpatient treatment
depression has decreased the presentation of patients with
overdose of these agents. Because depressed patients are
e most susceptible to purposeful drug overdoses, pharma-
utical manufacturers have attempted to create multiple new
tidepressants such as selective serotonin reuptake inhibitors
r use in depression (50). Despite this, TdP has been reported
patients with overdoses of these medications, such as
talopram (50). Other nontricyclic antidepressants, such as
azodone, have also been implicated in TdP in patients with
rposeful overdose (51). Moreover, a recent analysis of
rrent users of older typical versus newer atypical antipsy-
otic agents revealed that both groups had a similar dose-
lated increased risk of sudden cardiac death compared with
atched nonusers of antipsychotic drugs (52).
Chronic administration of amiodarone markedly prolongs
e QT interval, yet it is very rarely associated with TdP (53).
has been postulated (although as yet unproven) that unlike
gh-risk drugs that selectively prolong repolarization in
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March 2, 2010:934–47 Prevention of Torsade de Pointes in Hospital Settingsyocytes located in the mid myocardium (M cells), amioda-
ne uniformly delays repolarization in all layers of the
yocardial wall. As a result, there is only QT prolongation
d no transmural heterogeneity of repolarization, which is
e necessary substrate for the development of a reentrant
rhythmia. Another theory regarding the low TdP risk nature
amiodarone suggests that the drug also inhibits the phys-
logical late sodium currents that ultimately produce the
rhythmia (54).
This theory also applies to verapamil, a relatively potent IKr
ocker (55) that has never been associated with TdP,
obably because it is a much more potent blocker of L-type
lcium channels. The newer antianginal agent ranolazine
so blocks IKr (56,57), but the extent of the QT prolongation
pears limited during long-term therapy, probably because
e drug also blocks the physiological late sodium current. In
large clinical trial, ranolazine was not associated with an
creased incidence of TdP (58).
Intravenous administration can be associated with higher
ug concentrations and greater cardiac exposure than corre-
onding oral dosing. Thus, the intravenous route may be a
sk factor for TdP. In addition, there are provocative data
om an animal model of TdP that suggest that rapid infusion
ay be more likely to cause the arrhythmia than slower
fusion (of higher drug doses) (59). The mechanism under-
ing this effect is unknown but may reflect differential drug
livery to various sites within the myocardium.
The Arizona Center for Education & Research on
herapeutics maintains an updated list of drugs that have a
sk of causing TdP on their World Wide Web site at
ww.qtdrugs.org. Table 1 shows a drug list from this World
ide Web site that has been modified to exclude amiodarone
egarded as low risk) and drugs that are no longer available
the United States. Table 1 represents the most common
ugs that can be implicated in TdP, but it is not a complete
t of all reported possible contributing substances. Impor-
ntly, the drugs listed in Table 1 are not equipotent in their
sk of causing TdP. For example, the risk of TdP ranges from
proximately 0.001% for Propulsid (cisapride) to approxi-
ately 8% for the antiarrhythmic quinidine. We also reem-
asize that the use of these medications may be clearly
dicated from a risk-benefit perspective despite the presence
the possibility of drug-induced TdP. For example, a recent
alysis of a large number of surgical patients (290 000)
vealed no change in the incidence of TdP in patients who
ceived antiemetic therapy with low-dose droperidol versus
ose without droperidol therapy (60). Therefore, in an
dividual patient, a drug listed in Table 1 may provide a
erapeutic benefit that outweighs its risk of causing TdP.
dP Risk Factors and Exacerbating
onditions in Hospital Settings
isk factors for the development of TdP in hospitalized
tients are listed in Table 2, along with references to clinical
ta, reviews and meta-analyses, and selected experimental
udies. Clinically recognizable historical, ECG, and labora-
ry risk factors are emphasized (61–65), but the potential
le for analyses of predictive genetic polymorphisms as risk markers is also noted (26,66–69). The term repolarization
serve was introduced by Roden (70), who explained that
rmal cardiac repolarization depends critically on the inter-
ay of multiple ion currents, and these provide some redun-
ncy, or reserve, to protect against excessive QT prolonga-
n by drugs. Roden proposed that lesions in these
polarizing mechanisms that result in reduced repolarization
serve can remain subclinical but nevertheless increase risk
drug exposure.
In hospitalized patients, TdP is commonly associated with
quired prolongation of the uncorrected or rate-corrected QT
terval (71–74), with or without underlying genetic predis-
sition (24), often in the presence of a noncardiac drug that
known (or not known) to prolong the QT interval (75–77).
f note, the risk for TdP increases significantly with concur-
nt use of more than 1 QT prolonging drug (78–80), and
ncomitant medication or intrinsic disease that alters liver
etabolism of 1 or more of these drugs also increases risk
6,79). Accordingly, careful examination of administered
ugs can identify patients who should have continuous ECG
ble 1. Drugs that Have a Risk of Causing Torsade de Pointes*
eneric Name
Brand
Name(s) Clinical Use
senic trioxide Trisenox Cancer/leukemia
pridil Vascor Antianginal
loroquine Aralen Antimalarial
lorpromazine Thorazine Antipsychotic, schizophrenia, antiemetic
sapride Propulsid Gastrointestinal stimulant
arithromycin Biaxin Antibiotic
sopyramide Norpace Antiarrhythmic
fetilide Tikosyn Antiarrhythmic
operidol Inapsine Sedative, antiemetic
ythromycin E.E.S.,
Erythrocin
Antibiotic, increase gastrointestinal
motility
lofantrine Halfan Antimalarial
loperidol Haldol Antipsychotic, schizophrenia, agitation
tilide Corvert Antiarrhythmic
vomethadyl Orlaam Opiate agonist, pain control, narcotic
dependence
esoridazine Serentil Antipsychotic, schizophrenia
ethadone Dolophine,
Methadose
Opiate agonist, pain control, narcotic
dependence
ntamidine NebuPent,
Pentam
Antiinfective, pneumocystis pneumonia
mozide Orap Antipsychotic, Tourette tics
ocainamide Pronestyl,
Procan
Antiarrhythmic
inidine Quinaglute,
Cardioquin
Antiarrhythmic
talol Betapace Antiarrhythmic
arfloxacin Zagam Antibiotic
ioridazine Mellaril Antipsychotic, schizophrenia
*Drugs with low risk and drugs no longer available in the United States are
t included in this table. Modified from the Arizona CERT World Wide Web site
www.qtdrugs.org on April 18, 2009.onitoring.
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Prevention of Torsade de Pointes in Hospital Settings March 2, 2010:934–47Multiple studies have shown that risk for TdP among
spitalized patients is strikingly greater in women than in
en, by a factor of approximately 2-fold (72,73,75–77,79,
–85). TdP is more common in patients older than 65 years
an in younger patients (75,77,86). Predisposition to the
velopment of TdP has been associated with underlying
art disease of multiple origins (39,64,65,73,75,76). Hypo-
lemia, perhaps by modifying the function of the IKr channel
prolong the QT interval in a manner that results in
terogeneity and dispersion of repolarization, is a well-
tablished predisposing risk factor for TdP (46,74,87–90), as
hypomagnesemia (89,91–94). Hypocalcemia, which also
olongs the QT interval, has been associated with TdP only
rare cases (95,96). The association of diuretic use with
-hospital TdP may be explained by its correlation with
ngestive heart failure, hypokalemia, and hypomagnesemia
2,74). In addition, some diuretics directly block potassium
rrents and may therefore reduce repolarization reserve (97).
travenous potassium has been shown to reverse the QT-
olonging effects of quinidine in humans (90), but the value
acute potassium repletion is less well documented than that
intravenous magnesium for the acute treatment of drug-
duced TdP (64,65,91,92). Normal levels of both potassium
d magnesium should be maintained aggressively in hospi-
lized patients at risk.
Bradycardia is an additional important risk factor for TdP
patients when other predisposing findings are present
5,87). Prolonged ventricular cycle length can take the form
simple sinus bradycardia, complete atrioventricular block,
ble 2. Risk Factors for Torsade de Pointes in
spitalized Patients
inically recognizable risk factors (61–65)
QTc 500 ms (71–74)
LQT2-type repolarization: notching, long Tpeak–Tend (11,12)
Use of QT-prolonging drugs (75–77)
Concurrent use of more than 1 QT-prolonging drug (78–80)
Rapid infusion by intravenous route (59)
Heart disease (64,73,75,76)
Congestive heart failure (39)
Myocardial infarction (39,73)
Advanced age (75,77,86)
Female sex (64,72,73,75–77,79,81–85)
Hypokalemia (46,74,87–90)
Hypomagnesemia (89,91–94)
Hypocalcemia (95,96)
Treatment with diuretics (72,74,97)
Impaired hepatic drug metabolism (hepatic dysfunction or drug-drug
interactions) (76,79)
Bradycardia (65,87)
Sinus bradycardia, heart block, incomplete heart block with pauses
(98,99)
Premature complexes leading to short-long-short cycles (65,72)
Multiple clinically recognizable risk factors (64,65,76,79,84)
inically silent risk factors
Occult (latent) congenital LQTS (23,64)
Genetic polymorphisms (reduced repolarization reserve) (26,27,31,66–69)any rhythm in which sudden long cycles may lead to 48rhythmogenic early afterdepolarizations (98,99). Premature
ats that lead to short-long-short cycles may foster the
velopment of TdP (65,72). In contrast, isoproterenol infu-
on or overdrive pacing can suppress TdP in these circum-
ances. Interestingly, and despite the association with short-
ng-short cycles, the risk for TdP appears to be decreased
hen the underlying rhythm is atrial fibrillation, unless there
also complete heart block (100).
At present, no quantitative multivariate risk index exists for
e prediction of TdP in the hospital-based population.
rhaps the greatest risk for the development of TdP in the
spital setting occurs with the clustering of multiple recog-
zable risk factors in a single patient (64,65,76,79,84).
ccordingly, an elderly woman with diuretic-treated heart
ilure taking more than 1 potentially QT-prolonging drug
ith sinus bradycardia and occasional ventricular bigeminy
ould be a good candidate for ECG/QTc monitoring and
ectrolyte repletion.
ethods to Monitor QT/QTc in
ospital Settings
r many years, periodically recorded standard 12-lead ECGs
ve been relied on in hospital settings to measure QT
tervals and to provide a heart-rate–corrected QT interval
Tc). In hospital units with continuous ECG monitoring,
anual measurement of QT intervals with handheld calipers
ing rhythm strips from bedside cardiac monitors has also
en performed. Traditionally, the Bazett correction has been
ed to adjust measured QT for cycle length by dividing the
served, uncorrected QT interval by the square root of the
-R interval (in seconds). When not otherwise stated, QTc
nerally refers to the Bazett correction. It has become
creasingly well recognized that the Bazett correction tends
produce overlong QTc values at faster heart rates, partic-
arly above 85 beats per minute, as is commonly found in
spitalized patients. Alternative QTc calculation methods
e available, including both linear and nonlinear corrections
at adjust more appropriately at faster rates. Alternative QT
rrections, such as the Fridericia formula (which divides
served QT by the cube root of cycle length), are likely to
d increasing roles in hospital monitoring settings in the
ture (101–103).
Several monitor manufacturers now provide electronic
lipers, which can be used to measure the QT and R-R
tervals in a computer-assisted fashion. Most recently, a fully
tomated hospital monitor system for real-time QT/QTc
onitoring has been introduced (104). There are no research
udies to indicate the best method for monitoring QT/QTc
tervals in hospital settings; thus, what follows is a descrip-
n of measurement strategies used in current clinical prac-
e, with comments about their benefits and pitfalls.
efinition of Prolonged QT Interval
he expert writing group recommends that a QTc over the
th percentile should be considered abnormally prolonged.
pproximate 99th percentile QTc values for otherwise
althy postpubertal individuals are 470 ms for males and
0 ms for females (Figure 3). For both males and females, a
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March 2, 2010:934–47 Prevention of Torsade de Pointes in Hospital SettingsTc500 ms is considered highly abnormal (7–9). It must be
pt in mind, however, that some standard 12-lead ECG
gorithms label a QTc 440 ms as borderline QT prolonga-
n, despite the fact that this value is exceeded by approxi-
ately 10% to 20% of the population.
anual Measurement
he QT interval is measured from the beginning of the QRS
mplex to the end of the T wave and approximates the time
takes the ventricles to repolarize (i.e., a body-surface
timation of the cellular action potential duration). If the
tient develops a wide QRS complex (e.g., due to a new
ndle-branch block), this will increase the total QT interval.
ch an increase of the QT interval due to a new conduction
ock should not be considered indicative of acquired LQTS
d risk for TdP (105). One method to adjust the QT
easurement after the development of a bundle-branch block
to subtract the difference in QRS widths before and after
e block. Another method is to measure a J-T interval from
e end of the QRS complex to the end of the T wave, which
iminates the QRS in the measurement altogether. The
portant point, however, is that if an adjustment method is
ed, it needs to be applied consistently when a patient is
ing monitored over time.
Although the onset of the QRS complex is usually readily
parent, the end of the T wave is often obscure, especially
hen T waves are of low amplitude or T-U distortion is
esent in drug-induced states. The lead recommended for
anual QT measurement is the one from the patient’s 12-lead
CG that has a T-wave amplitude of at least 2 mm and a
ell-defined T-wave end. Thus, the lead choice will vary
ong patients. Because of the variation in QT interval
rations across the 12 leads, it is important to measure the
T interval in the same lead in a given patient over time and
document the lead being used. In situations in which the
d of the T wave may be difficult to determine (e.g., biphasic
notched T waves, T waves with superimposed U waves),
gure 3. QTc distribution curves in normal males and females and
a cohort of patients with congenital LQTS. Upper limits of nor-
al (99th percentile) for QTc are 470 ms in males and 480 ms in
males. For both males and females, a QTc 500 ms is consid-
ed dangerous. OR indicates odds ratio; RR, relative risk.e end of the T wave can be determined by drawing a line atom the peak of the T wave following the steepest T-wave
wnslope (106). The intersection of this line with the
oelectric baseline is considered the end of the T wave.
Calculation of QTc in the setting of atrial fibrillation is
allenging, because the QT interval varies from beat to beat
pending on the varying RR intervals. One way to deal with
e irregularity of the rhythm is to identify the shortest and
ngest R-R intervals, calculate the QTc for each, and average
e 2 QTc values. Alternatively, a long rhythm strip can be
inted to determine whether, on average, the interval from R
ave to the peak (or nadir) of the T wave is more than 50%
the R-R interval. This does not give an exact QTc value but
ovides an indication that it would be longer than the critical
reshold of 500 ms if measured.
lectronic Calipers
he current generation of hospital ECG monitoring systems
ovides a computer-assisted tool (electronic calipers) for
T-interval measurement. When electronic calipers are used,
creasing the size of waveforms from a standardization of 1
2, 3, or 4 and increasing the recording speed from 25 to 50
m/s can enhance visualization. The electronic calipers are
oved to the beginning of the QRS complex and the end of
e T wave, and the resulting value is entered. The preceding
-R interval is then measured in the same fashion. Several
onitor manufacturers have a QTc calculator built into their
ectronic caliper systems so when the QT and R-R intervals
e entered, the system calculates the QTc and prints the value
the rhythm strip. Because electronic caliper systems
pend on humans to select the appropriate ECG lead and to
entify the measurement onset and offset points, measure-
ent of the QT interval with electronic calipers is prone to the
me error as manual measurement.
ully Automated QT/QTc Monitoring
he current standard practice of periodic manual measure-
ent of the QT interval, and even the use of electronic
lipers, has drawbacks. For example, error can occur in
termining the beginning or end of the QT interval, in the
plication of a heart rate–correction formula, and from
consistency in the choice of lead for QT measurement
07). In addition, random selection of 1 beat in 1 lead is
ely not to be representative, because significant beat-to-
at variation exists not only because of manual measurement
ror but also due to actual QT-interval changes. Moreover,
velopment of bundle-branch blocks or irregular rhythms,
ch as atrial fibrillation, compounds the problem of QT
easurement.
Because of the difficulty and unreliability of manual
easurement, Helfenbein et al. (104) reported the develop-
ent and laboratory testing of an algorithm to measure
T/QTc intervals continuously in real-time using bedside
onitors. The algorithm measures QT/QTc intervals every 5
inutes. An audible alarm sounds if there is an increase in
Tc 60 ms from baseline (first measurement unless reset
anually before drug administration) or a QTc 500 ms for
least 3 consecutive measurements (15 minutes).
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Prevention of Torsade de Pointes in Hospital Settings March 2, 2010:934–47ifferences in QT Measurements Between
tandard 12-Lead Electrocardiographs
anufacturers of electrocardiographs have proprietary and
ten substantially different computer algorithms for QT-
terval measurement (108). In addition, 2 standard 12-lead
ectrocardiographs may differ substantially in their QT
easurement depending on when they were manufactured
09). Newer electrocardiographs typically use global QT
easurements derived from simultaneous multilead acquisi-
n, whereas older electrocardiographs typically use single-
ad measurement. Therefore, if serial comparisons of QT
tervals are being made with standard 12-lead ECGs, the
me electrocardiograph instrument should be used so that
y observed QT-interval increase is truly due to prolonga-
n of ventricular repolarization rather than a change in
mputer algorithm.
ractical Considerations in
T/QTc Monitoring
ccording to the American Heart Association’s practice
andards for ECG monitoring in hospital settings (110),
dications for QT-interval monitoring include the following:
initiation of a drug known to cause TdP; 2) overdose from
tentially proarrhythmic agents; 3) new-onset bradyarrhyth-
ias; and 4) severe hypokalemia or hypomagnesemia. Be-
use there is often a lack of clarity with regard to the types
d amounts of drugs taken in an intentional overdose
tuation, it is prudent to monitor QT intervals in all overdose
ctims.
Until fully automated QT/QTc monitoring is validated and
idely available in clinical settings, a reasonable strategy is
document the QTc interval before and at least every 8 to 12
urs after the initiation, increased dose, or overdose of
T-prolonging drugs. If QTc prolongation is observed, more
equent measurements should be documented (111). How
ng QTc measurement should be continued depends on the
ug half-life, how long it takes for the drug to be eliminated
om the body (which may depend on renal or hepatic
nction), whether the drug is given once versus as ongoing
erapy, how long it takes for the QTc to return to the predrug
seline, and whether the ECG shows QT-related arrhyth-
ias. For example, the drug ibutilide, which is administered
a 1-time treatment for termination of atrial fibrillation or
tter, was reported to cause TdP in 4.3% of 586 patients;
wever, all but 1 arrhythmia episode occurred within 1 hour
the end of infusion, and none occurred after 3 hours (112).
hus, it is unnecessary to monitor QTc after 3 hours in
tients who receive a 1-time ibutilide dose.
ummary and Recommendations for
onitoring QT/QTc in Hospital Settings
ecause hospitals differ with respect to their cardiac moni-
ring equipment, there is no one-size-fits-all strategy that can
recommended. For example, Hospital A may have a fully
tomated QT-monitoring system, whereas Hospital B has
ly the computer-assisted electronic caliper feature. Of
most importance, however, is that a hospital protocol be
tablished so that a single consistent method is used by all avalthcare professionals charged with the responsibility for
rdiac monitoring. The protocol should stipulate the equip-
ent to use for QT measurement, the method to determine the
d of the T wave, the formula for heart rate correction,
ad-selection criteria, (e.g., the lead that has a visible T wave
ith a clear-cut ending), and the importance of measuring the
me lead in the same patient over time.
anagement of Drug-Induced
T Prolongation and TdP in
ospital Settings
rug-Induced Prolonged QT
he 2006 American College of Cardiology/American Heart
ssociation/European Society of Cardiology guidelines for
anagement of patients with ventricular arrhythmias (34)
ake relatively few recommendations on prevention of TdP
the hospital setting. The guidelines do recommend removal
the offending agent in patients with drug-induced LQTS
lass I, Level of Evidence: A); however, they do not define
hat QTc value should prompt such discontinuation.
Continuous QTc monitoring is appropriate for drugs
emed most at risk to cause not only QT prolongation but
so TdP. After administration of an at-risk drug, if the QTc
ceeds 500 ms or there has been an increase of at least 60 ms
mpared with the predrug baseline value, especially when
companied by other ECG signs of impending TdP, prompt
tion is indicated. Appropriate actions include alternative
armacotherapy; assessment of potentially aggravating
ug-drug interactions, bradyarrhythmias, or electrolyte ab-
rmalities; and the ready availability of an external defibril-
tor. Patients should not be transported from the unit for
agnostic or therapeutic procedures, and they should be in a
it with the highest possible ECG monitoring surveillance.
onsustained and Sustained TdP
r patients with TdP that does not terminate spontaneously
that degenerates into ventricular fibrillation, immediate
rect-current cardioversion should be performed. The guide-
e (34) states that intravenous magnesium sulfate is reason-
le for patients taking QT-prolonging drugs who present
ith episodes of TdP and a prolonged QT interval (Class IIa,
evel of Evidence: B). Magnesium sulfate 2 g can be infused
travenously as a first-line agent to terminate TdP irrespec-
e of the serum magnesium level (113). If episodes of TdP
rsist, it may be necessary to repeat infusions of magnesium
lfate 2 g. The mechanism underlying the protective effect of
agnesium is unknown. An increase in heart rate to prevent
uses that may trigger TdP may be attempted with tempo-
ry transvenous atrial or ventricular pacing at rates 70
ats per minute (114). Repletion of potassium to suprathera-
utic levels of 4.5 to 5 mmol/L may also be considered,
though there is little evidence to support this practice (Class
b, Level of Evidence: C) (34).
ospital Discharge
hen discharged, the patient should be educated about
oiding the culprit drug, other related drugs, and potential
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ugs (available at www.qtdrugs.org) should be provided to
e patient and appropriate documentation made in the
edical record. If drug-induced TdP has occurred, a careful
view of the patient’s personal and family history should be
tained, because it may be the sentinel event heralding the
esence of congenital LQTS (23). If a personal/family
story of unexplained syncope or premature sudden death
erges, a 12-lead ECG should be recommended for all
st-degree relatives, and consideration should be given to
inically available genetic testing for congenital LQTS.
ummary
dP is an uncommon but potentially fatal arrhythmia that can
caused by drugs that cause selective prolongation of action
tential durations in certain layers of the ventricular myo-
rdium, which creates dispersion of repolarization and a
ng, distorted QT-U interval on the ECG. A summary of key
ints to remember is provided in Table 3.
For patients who receive QT-prolonging drugs in hospital
its with continuous ECG monitoring, TdP should be
oidable if there is an awareness of individual risk factors
d the ECG signs of drug-induced LQTS. Particularly
portant are the ECG risk factors for TdP, including marked
Tc prolongation to 500 ms (with the exception of
iodarone- or verapamil-induced QT prolongation), marked
T-U prolongation and distortion after a pause, onset of
ntricular ectopy and couplets, macroscopic T-wave alter-
ns, or episodes of polymorphic ventricular tachycardia that
e initiated with a short-long-short R-R cycle sequence
ypically, PVC–compensatory pause–PVC). Recognition of paese ECG harbingers of TdP allows for treatment with
travenous magnesium, removal of the offending agent, and
rrection of electrolyte abnormalities and other exacerbating
ctors, including the prevention of bradycardia and long
ble 3. Summary of Key Points
Drugs associated with TdP vary greatly in their risk for arrhythmia; an
updated list can be found at www.qtdrugs.org.
Risk factors for drug-induced TdP include older age, female sex, heart
disease, electrolyte disorders (especially hypokalemia and
hypomagnesemia), renal or hepatic dysfunction, bradycardia or rhythms
with long pauses, treatment with more than 1 QT-prolonging drug, and
genetic predisposition.
The risk-benefit ratio should be assessed for each individual to
determine whether the potential therapeutic benefit of a drug outweighs
the risk for TdP.
After initiation of a drug associated with TdP, ECG signs indicative of risk
for arrhythmia include an increase in QTc from predrug baseline of 60
ms, marked QTc interval prolongation 500 ms, T-U wave distortion that
becomes more exaggerated in the beat after a pause, visible
(macroscopic) T-wave alternans, new-onset ventricular ectopy, couplets
and nonsustained polymorphic ventricular tachycardia initiated in the
beat after a pause.
In monitoring QT intervals in an individual before and after drug
administration, a consistent method should be used (i.e., same recording
device, ECG lead, measurement tool [automated or manual], and heart
rate–correction formula).
Recommended actions when ECG signs of impending TdP develop are to
discontinue the offending drug, replace potassium, administer magnesium,
consider temporary pacing to prevent bradycardia and long pauses, and
transfer the patient to a hospital unit with the highest level of ECG
monitoring surveillance where immediate defibrillation is available.uses with temporary pacing if necessary.
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